CORAL SPRINGS, Florida, July 6, 2016 /PRNewswire/ --
Revenue forecasts for the cannabis industry in the United States continue to skyrocket as more states move towards legalization and companies develop innovative services and products to maximize earning potential. More and more big business entities are becoming involved in the lucrative cannabis sector as marijuana projects and opportunities explode in U.S.
Freedom Leaf, Inc., (OTC: FRLF) a budding publishing & multimedia company in the rapidly growing medical/recreational Marijuana & Industrial Hemp industry has set up a financial services division that will include an Incubator/Accelerator to assist companies in the legal Cannabis/Hemp Industry. It will not only work at incubating new companies but it will also seek companies to acquire to add to the growth and reach of Freedom Leaf, Inc., a fully reporting and audited public company. Jon Doukas a principal investor in the Cannabis space had this to say: "Freedom Leaf is uniquely positioned in its role as a leading trade publication to source out those newly emerging start-ups and together with Blue Moon Consortium to incubate the best and the most promising in the cannabis space."
Read the full Freedom Leaf (FRLF) Press Release at: http://financialnewsmedia.com/profiles/frlf.html
Last week, Freedom Leaf, Inc., entered into a Mutual Letter of Understanding to acquire a legacy specialty apparel company, http://www.Hippo-Tees.com. Freedom Leaf CEO, Cliff Perry stated, "The addition of the Hippo-Tees brand and founder, Jeffrey Axelrod's 46 years of merchandising experience under the Freedom Leaf umbrella fills a necessary purpose for promotions, branding and marketing. Mr. Axelrod has the experience to not only manage the T-Shirt line but any product lines that are required to fulfill our clients and Freedom Leaf's needs. In specialty merchandising, T-Shirts, Polos and Sport shirts represent $5 billion in sales, far surpassing any other category."
In other industry related news and recent happenings: PharmaCyte Biotech, Inc. (OTC: PMCB) (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced that a recently published scientific article supports PharmaCyte's ongoing research efforts that concern medical uses for constituents of Cannabis known as cannabinoids. The article titled "Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids" was published in the journal, Aging and Mechanisms of Disease and appeared online on June 23, 2016. The article can be viewed in its entirety at http://www.nature.com/articles/npjamd201612
Terra Tech Corp. (OTC: TRTC) (OTCQX: TRTC), a vertically-integrated, cannabis-focused agriculture company, recently announced it has expanded its offering of the IVXX Vape Product line with the launch of the "Z92" cartridges, the second line of cannabis oil cartridges. This follows the launch of the Company's original Z35 cannabis oil cartridge line in April 2016. Terra Tech's pre-filled cartridges are offered in a variety of cannabis strains which are easy-to-use and are conveniently designed for vaporizers as well. IVXX Z92 cartridges have a Tetrahydrocannabinol (THC) content level between 75 to 85 percent compared with the 60 to 68 percent of the Z35s. Made from local, sustainably grown cannabis that has been cleanly extracted using supercritical CO2, the oil is lab-formulated for consistency, and lab-tested for purity and potency. Through its low heat refinement technique and a unique filtering method, the Company maintains the natural terpene profile of each strain. There is no reintroduction of terpenes or flavor enhancers at any time in the process, as is true with all IVXX products.
Insys Therapeutics, Inc. (NASDAQ: INSY) this week announced that the U.S. Food and Drug Administration (FDA) has approved Insys' dronabinol oral solution, SyndrosTM, an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a pharmaceutical version of tetrahydrocannabinol ("THC"). Syndros is approved for use in treating anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Syndros is currently awaiting scheduling by the U.S. Drug Enforcement Administration. "We are very pleased to announce FDA approval of Syndros. We believe that Syndros will be an important new treatment option for patients suffering from the devastating effects of chemotherapy induced nausea and vomiting, as well as those fighting anorexia associated with weight loss in AIDS," said the Company's Chairman, CEO and President, Dr. John N. Kapoor.
22nd Century Group, Inc. (NYSE: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced last week that the journal Alcoholism: Clinical and Experimental Research has published a new independent study concluding that switching to the Company's Very Low Nicotine cigarettes may lead not only to a reduction in smoking, but also to a reduction in alcohol use. This study employed 22nd Century's proprietary SPECTRUM® research cigarettes and was funded by National Institute on Drug Abuse (NIDA), the FDA Center for Tobacco Products, and the National Institute on Alcohol Abuse and Alcoholism.
FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit financialnewsmedia.com for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at financialnewsmedia.com. Follow us on Facebook: facebook.com/financialnewsmedia and Twitter: twitter.com/FNMgroup.
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNMG has been compensated one thousand nine hundred dollars for news coverage of the current press release issued by Freedom Leaf, Inc by a non-affiliated third party. FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
SOURCE FN Media Group LLC